ReviewPublished 12 October 2026Obesity-driven inflammation and immune dysregulation in cancer development and progressionPritika Pandey · Jeb F. Struder · Erika T. Rezeli · Evan M. Paules · Stephen D. Hursting · Michael F. Coleman · Kristin A. AltweggFrontiers in Oncologydoi 10.3389/fonc.2026.1947958
ReviewPublished 12 October 2026Antitumor immunity and immune-related toxicity during immune checkpoint inhibition: mechanistic overlap, tissue selectivity, and interventional evidenceChengyan Shi · Chunhai Li · Jun YanFrontiers in Immunologydoi 10.3389/fimmu.2026.1958441
Original ResearchPublished 12 October 2026Early dynamics of eosinophils and the neutrophil-to-lymphocyte ratio are associated with severe immune-related adverse events during nivolumab therapy for metastatic renal cell carcinomaOndřej Fiala · Jan Králíček · Jindřich Kopecký · Michal Vočka · Tomas Buchler · Hana Študentová · Jana Obertová · Beáta Rondzíková · Martin Matějů · Dominik Šafčák · Matej Hrnčár · Peter Priester · Martina Spisarová · Anežka Zemánková · Radka Lohynská · Michaela Tkadlecová · Lucie Grmelová · Petr Stránský · Bohuslav Melichar · Patrik Palacka · Alexandr PoprachFrontiers in Immunologydoi 10.3389/fimmu.2026.1944728
ReviewPublished 23 September 2026Immunosuppressive cell populations as potential drivers of extrinsic immune checkpoint inhibition resistance in clear cell renal cell carcinomaUsman Humayun TemuriOncology Reviewsdoi 10.3389/or.2026.1953850
Case ReportPublished 4 September 2026Case Report: Pembrolizumab–induced myasthenia gravis with isolated anti-titin antibody positivity after thymectomy for thymomaJu Hye Kim · Ji Yeon Chung · Jeong Bin BongFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1932554
Case ReportPublished 23 January 2026Case Report: Durable response to PD-1 blockade after failure of ALK-targeted therapy and chemoimmunotherapy in ALK-positive large B-cell lymphomaGuilherme Gasparini Spiandorelo · Ahmed Alnughmush · Olivia Crum · Dragan Jevremovic · J. C. VillasboasFrontiers in Hematologydoi 10.3389/frhem.2025.1683981
